News from Kitos
Olaparib significantly improved progression-free survival in patients with advanced BRCA-mutated ovarian cancer. These results were shown on 21th of October at ESMO 2018. The SOLO-1 study is the first to evaluate maintenance therapy with Olaparib, an ADP-ribose polymerase-1 (PARP-1) inhibitor, after platinum-based chemotherapy in advanced ovarian carcinoma with BRCA1/2 mutation.
Of the 391 patients with complete or partial response after chemotherapy and enrolled in the study, 260 received a 300 mg Olaparib tablet twice a day for two years and 130 placebo (one patient did not receive placebo). The analysis of free-progression survival* showed a 70% reduction in the risk of tumor progression or death in Olaparib-treated group. Furthermore, there were no clinically relevant changes in the quality of life, and the dosage was well tolerated with only 12% of patients who discontinued the intake of Olaparib because of its toxicity. Although more time is needed to evaluate benefits in the overall survival**, these results show how treatment is effective and well tolerated, promising to improve current treatments of BRCA mutated ovarian carcinomas.
Original link of the ESMO congress
*Progression free survival: Survival free from tumor progression. The period of time during and after treatment during which a patient lives with the disease but does not get worse.
** Overall survival: Global survival. The period of time between the date of diagnosis or the start of treatment during which the patient is still alive.
Your comment will be posted after it is approved.
Leave a Reply.